PCSK9 Coverage: Payers Wrestling With Proving Statin Intolerance
Executive Summary
Confirmation of statin intolerance is likely to be among extensive prior authorization requirements that must be satisfied before payers approve coverage for the new class of cholesterol-lowering drugs.
You may also be interested in...
CVS Health Seeks Return To LDL Treatment Targets To Control PCSK9s
Broad nature of latest cholesterol treatment guidelines makes it hard to deploy utilization management programs to control use of pricey new PCSK9 inhibitors, CVS Health argues in JAMA editorial.
Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends
In shifting away from specific targets and non-statin add-on therapies, new ACC/AHA cholesterol guidelines support treatment of people at relatively low risk for events and more intensive therapy for those at higher risk.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.